Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) announces that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with Apozeal Pharmaceutical Inc. (“Apozeal”), a pharmaceutical company focused on the development and manufacturing of high-quality, cost-effective medicines. The proposed transaction represents a strategic step in advancing Tevogen Generics, established to support domestic pharmaceutical manufacturing and enhance affordability and national supply chain resilience.
Read the full article: Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal Pharmaceutical //
Source: https://www.globenewswire.com/news-release/2026/03/05/3250593/0/en/Tevogen-Advances-Generics-Strategy-Signs-Letter-of-Intent-to-Evaluate-Potential-Acquisition-of-Apozeal-Pharmaceutical.html